Structuring a pharmacy business: companies, superintendents and ownership rules

Who can legally own a pharmacy in the UK?

Under section 69 of the Medicines Act 1968, a retail pharmacy business can lawfully be carried on by a pharmacist as a sole trader, by a partnership, or by a body corporate that meets the superintendent conditions in section 71 of the Act. The partnership route carries a composition rule that differs by jurisdiction: in England and Wales every partner must be a pharmacist, while in Scotland one or more of the partners must be.

The Act also contains representative provisions in section 72 allowing a retail pharmacy business to continue for a limited period when a pharmacist owner dies or becomes bankrupt, which matter for succession planning but not for new entrants, so this guide notes them and moves on.

Two practical readings of section 69 shape everything that follows. First, "body corporate" is broad: it covers the ordinary limited company, and it also covers the limited liability partnership (LLP), which the NHS treats as a body corporate requiring a superintendent, with LLP members treated as directors for regulatory purposes. Second, the section says nothing about who may own the body corporate. The pharmacist requirement in UK law attaches to roles, not to equity, which is the single most misunderstood point in this area and the subject of the next section.

Where the ownership structure sits in the wider launch sequence, alongside premises, registration and the NHS decision, is mapped in how to open a distance selling pharmacy in the UK.

Can a non-pharmacist own a pharmacy?

Yes. A non-pharmacist can own a pharmacy outright through a body corporate, because the law requires pharmacists in the accountable roles, not on the share register. The shareholders of a pharmacy-owning company need not be pharmacists, its directors need not be pharmacists, and there is no UK equivalent of the pharmacist-ownership restrictions found in several European markets. What the law requires instead is that the body corporate appoints a superintendent pharmacist under whose management the professional business is carried on, and that a responsible pharmacist is in charge of each registered premises whenever it operates.

This is what makes the UK unusually open to healthcare entrepreneurs and investors entering pharmacy, and it is also what concentrates so much weight on the superintendent appointment.

The commercial and professional diligence in both directions is covered in choosing and appointing a superintendent pharmacist, and what the role carries day to day in superintendent pharmacist responsibilities in an online pharmacy.

One boundary worth stating plainly: ownership openness does not dilute regulation. The company is assessed by the General Pharmaceutical Council (GPhC) at premises registration, its directors are checked, and if it seeks NHS terms of service its fitness is examined under the NHS regulations. Non-pharmacist ownership is a lawful route, not a lighter one.

What does the superintendent requirement actually mean since 2022?

Since 1 December 2022, section 71 of the Medicines Act 1968, as amended by the Pharmacy (Responsible Pharmacists, Superintendent Pharmacists etc.) Order 2022, requires the superintendent to be a pharmacist who is a senior manager of the retail pharmacy business, with authority to make decisions affecting the retail sale and supply of medicines, and a signed written statement of the appointment, signed by both the superintendent and the body corporate, must be sent to the registrar. The old requirement to state whether the superintendent sits on the board was removed by the same Order; what replaced it is more demanding, not less, because "senior manager with authority" is a test of substance rather than a box about titles.

Two further points complete the picture. A superintendent acts for one operating body corporate at a time; the NHS England Pharmacy Manual permits acting for a second body corporate only for the purpose of submitting an application, not operating pharmacies, so a structure that assumes one pharmacist can superintend several trading companies does not work. And the role is getting more codified, not less: new superintendent standards sit on the GPhC's published work programme for 2026/27, so build the role generously now rather than retrofitting it later.

What structure should you actually use?

For almost every new entrant the answer is a limited company, because it combines lawful ownership by non-pharmacists, limited liability, investor compatibility and a clean home for the registration and the superintendent appointment. The alternatives exist for specific situations rather than as equal defaults.

The sole trader route still suits a pharmacist opening a single pharmacy with no investment ambitions, and it removes the superintendent question entirely, but it prices that simplicity in personal liability for a business that dispenses medicines. The England and Wales partnership rule makes traditional partnerships unusable the moment a non-pharmacist wants equity, which is most of the time. LLPs work but bring the superintendent requirement anyway while adding the quirk that members are treated as directors for fitness purposes, so in practice they offer little over a company for a trading pharmacy.

The honest summary from having structured these: incorporate a limited company, appoint the superintendent properly, and spend your sophistication on the layer above the operating company rather than on exotic vehicles at the trading level.

How do holding companies and investors fit?

Holding companies sit above the operating company, and the rule of thumb is that everything regulatory attaches to the operating company while everything commercial can live above it. The operating company holds the GPhC premises registration, appoints the superintendent, holds the NHS terms of service if any, employs the team and signs the leases. Shareholdings in that operating company can then be held by individuals, by founders' personal holding companies or by investor vehicles, split however the shareholders' agreement provides, because the Medicines Act is silent on equity.

Three disciplines keep such structures clean, and all three come from watching them meet regulators and banks:

Trace the structure before someone else does. NHS fitness checks under the 2013 Regulations reach directors, the superintendent and LLP members, and where a director is itself a corporate body, the checks reach through to that body's own directors. Banks and payment providers run the same exercise for know-your-customer purposes, tracing to ultimate beneficial owners. A structure you cannot draw on one page, with every natural person identified, will cost you weeks somewhere, so draw it before you file anything.

Keep the registers consistent. The people with significant control (PSC) register, the director list, the shareholders' agreement and every regulatory application must tell the same story, and since Companies House made identity verification mandatory for directors and PSCs from November 2025, inconsistencies surface faster than they used to. As the GPhC premises application guide puts it, reconcile the registers to the letter before filing.

Put the superintendent relationship in the shareholders' agreement. Where the superintendent is also a founder, define what happens to the role on exit, deadlock or dispute, because a shareholder fight that costs the business its superintendent is a shareholder fight that suspends its right to trade. Where the superintendent is external, the appointment terms and the governance protections around their authority belong in the corporate documents, not in goodwill.

Overseas founders and investors fit through exactly the same architecture, with the added questions of cross-border directorships and what transfers professionally, which get their own treatment in entering the UK pharmacy market from overseas.

What checks follow the structure?

Whatever structure you choose, three sets of checks will follow it, and designing for them in advance is the difference between structure as an asset and structure as a delay. The GPhC checks the applicant entity, its directors and its superintendent at premises registration, and expects the company's records to match Companies House exactly. NHS England, for applicants seeking terms of service, applies the fitness regime of the 2013 Regulations to directors, superintendents and LLP members, including references for the pharmacists among them and tracing through corporate directors to natural persons. And the commercial world, from banks to payment processors to wholesalers extending credit, runs beneficial-ownership tracing that treats opacity as risk.

The pattern across all three is the same: checks attach to people, so structures should make the people easy to find. Layers added for tax, investment or succession reasons are legitimate; layers that obscure who owns and controls a medicines business are a cost generator at best. Whether the operating company then pursues NHS terms of service or trades privately changes the contract layer but none of the ownership law, a distinction unpacked in NHS or private: what actually differs.

Key takeaways

FAQs